MeiraGTx and Hologen launch AI-backed gene therapy venture

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from Hologen.

Leave a Reply

Your email address will not be published. Required fields are marked *